Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

Other authors

Institut Català de la Salut

[Sanchez-Salinas MA, Iacoboni G, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Miarons M] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Pharmacy Department, Consorci Hospitalari de Vic, Barcelona, Spain. [Troconiz IF] Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain. [Navarro V] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Varela J] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-05-16T11:32:58Z

2024-05-16T11:32:58Z

2024-05-14

Abstract

Fludarabina; Cèl·lules CAR-T


Fludarabina; Células CAR-T


Fludarabine; CAR-T cell

Document Type

Article


Published version

Language

English

Publisher

American Society of Hematology

Related items

Blood Advances;8(9)

https://doi.org/10.1182/bloodadvances.2023011433

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)